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Heart transplantationThrombotic microangiopathy (TMA) is a rare but serious complication of organ transplantation. This article
presents the first literature review on TMA following non-renal solid organ transplantation (SOT). Ischemia–
reperfusion, immunosuppressive drugs, acute interfering disease and a relative deficiency of the vonWillebrand
factor (vWF) cleaving protease (ADAMTS13) appear to play amajor role in its pathogenesis. De novo TMA occurs
in 4.0% of liver and 2.3% of lung transplant recipients, whereas the incidence remains unknown after intestinal
transplantation. The median time of onset is 2, 37 and 8 weeks after liver, lung and intestinal transplantations
respectively, with a three month survival of about 70%. In heart transplantation TMA is rare, occurrence is late
and prognosis is poor. In TMA early after liver transplantation an elevated vWF/ADAMTS13 ratio may show
diagnostic value. Early withdrawal of calcineurin inhibitors (CNI) proves to be lifesaving. Conversion to another
CNI and rechallenge after resolution are generally safe, except after heart transplantation. The value of plasma
exchange therapy remains controversial.
© 2014 Elsevier Ltd. All rights reserved.1. Introduction
TMA is a potentially fatal disorder characterized by formation of
platelet rich thrombi in the microcirculation, thrombocytopenia and
non-immune hemolytic anemia. The term thromboticmicroangiopathy
encompasses a spectrum of diseases, all defined by the same histopath-
ological lesions of the vessel wall, mainly arterioles or capillaries and es-
pecially those in the glomeruli. The lesions are characterized by a patchy
distribution and consist of vessel wall widening with swelling and de-
tachment of the endothelial cells from the basement membrane and
the accumulation of fluffy material in the subendothelium. This causes
intravascular platelet aggregationwith subsequent formation of platelet
rich thrombiwithin themicrocirculation and obstruction of vessel lumi-
na. The consumption of platelets combined with mechanical damage of
red blood cells, reflected by the presence of fragmented red blood cells,
results in the typical biochemical hallmark of thrombocytopenia and
microangiopathic hemolytic anemia. The classic pentad of signs, al-
though rarely all present, is further completed by the presence of
fever, renal failure and neurological symptoms [1].16 34 68 80 (secr.); fax: +32
erbiest),
uzleuven.be (D. Dierickx).
+32 16 87 43.
e novo thrombotic microangiTMAs, though uncommon, are of considerable clinical importance
because of their abrupt onset and high morbidity and mortality when
left untreated. Especially in the post-transplant setting, clinicians should
be aware of the risk of patients developing TMA. Early recognition and
therapeutic intervention can be lifesaving.
After giving a brief overview of the classification, clinical presenta-
tion and diagnosis of TMAs, we review the literature on non-renal SOT
associated TMA and review its pathogenesis and treatment in light of
these findings. Transplantation associated TMA (TA-TMA) after renal
and hematopoetic stem cell transplantation has already been described
extensively in literature and will be discussed only briefly [2–5].
1.1. Classification of thrombotic microangiopathies
Historically TMAs were largely considered to be two separate
disorders: thrombotic thrombocytopenic purpura (TTP) and hemolytic–
uremic syndrome (HUS). Idiopathic TTP is a condition characterized by
a deficiency of ADAMTS13, the vWF cleaving protease. This results in
the formation of ultralarge vWF multimers, leading to profound platelet
consumption, fragmentation of red blood cells and occlusion of small ves-
sels. Neurological signs and purpura are often more remarkable than
renal failure. The ADAMTS13 deficiencymay be genetic, but it is attribut-
ed to an autoimmunemechanism in amajority of patients. These patients
respondwell to therapeutic plasma exchange (PEX)which removes anti-
ADAMTS13 antibodies and provides newADAMTS13. The introduction of
PEX has improved survival from 10% to over 80% in this population [6].opathy after non-renal solid organ transplantation, Blood Rev (2014),
Table 1
Classic classification of the thrombotic microangiopathies.
Category Specific clinical features Etiology Treatment
Idiopathic TTP Often neurological signs. Severe renal failure is
uncommon. Sometimes associated with specific
conditions.
ADAMTS13 deficiency, mostly
autoimmune.
N80% response to plasma exchange. Corticosteroids,
rituximab.
Secondary TTP Associated with cancer, infection, hematopoietic
stem cell transplantation, solid organ transplantation,
chemotherapy, certain drugs.
Mostly unknown. ADAMTS13
deficiency is rare.
Dependent on the associated condition.
Diarrhea-associated HUS Bloody diarrhea followed by
acute renal failure.
Endothelial damage by Shiga toxin
producing bacteriae.
Supportive care.
Atypical HUS Acute renal failure. Complement regulatory
protein defects in at least 50%
of patients.
Supportive care. Sometimes kidney or liver–kidney
transplantation. Specific therapy according to the
specific defect (e.g. eculizumab).
TTP: thrombotic thrombocytopenic purpura. ADAMTS13: a disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13. HUS: hemolytic–uremic syndrome.
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failure dominates the clinical picture, caused by endothelial damage
by Shiga toxin producing bacteriae. It is generally preceded by bloody
diarrhea and PEX has proven not to be beneficial [7].
However, both conditions have turned out to share the same hall-
mark of thrombocytopenia and non-immune microangiopathic hemo-
lytic anemia, caused by identical endothelial lesions. Moreover a
multitude of other conditions characterized by the same pathological
mechanism has emerged. These were classified as either atypical HUS
(aHUS), in which acute renal failure is not associated with diarrheal
illness butmostly with complement regulatory protein defects, and sec-
ondary TTP, associated with a variety of precipitating factors like organ
transplantation, drugs, infection, pregnancy, autoimmune diseases and
cancer (Table 1) [8,9] Consensus grew that all of these disorders are
best described with the general histopathological term thrombotic
microangiopathy.
In clinical practice the terms TTP, secondary TTP, HUS and aHUS are
commonly used, sometimes leading to misunderstandings about their
exact etiology and appropriate treatment. In 2006 Besbas et al. proposed
a novel classification, based on etiology rather than clinical presentation
[10].1.2. Clinical presentation and differential diagnosis
In contrast to TMA after hematopoetic stem cell transplantation
(HSCT) uniform diagnostic criteria for TMA after SOT do not exist. This
not only complicates clinical practice, but also severely impedes analysis
of the literature.
In general, the presence of thrombocytopenia and Coombs negative
hemolytic anemia with no other cause in a SOT recipient is considered
to be TA-TMA. Early recognition is of major importance given its poor
prognosis without treatment.Table 2
Possible clinical and biochemical presentations of TMA.
Hallmark Clinic
Non-immune hemolytic anemia Fatigue, pallor, icterus
Thrombocytopenia Mucosal bleeding, purpura
Microvascular thrombosis
▪ Renal
▪ Cerebral
▪ Retinal
▪ Coronary
▪ Pulmonary
▪ Mesenteric
▪ Oliguria, hypertension
▪ Focal neurological deficit, c
▪ Visual disturbances
▪ Chest pain, conduction defe
▪ Diffuse alveolar hemorrhag
▪ Abdominal pain
LDH: lactate dehydrogenase.
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ifest systemically [11]. The presence of thrombocytopenia is mandatory
but is frequent after transplantation for various reasons. A sharp drop in
the platelet count however is rather typical of TMA and is often the first
sign [12,13]. The presence of Coombs negative anemia is alsomandatory
and is recognized by the presence of schistocytes on the peripheral
blood smear, elevated lactate dehydrogenase (LDH), reticulocytes and
bilirubin, and low haptoglobin levels. Impaired renal function or failure
is present inmost cases. Somepatients also presentwith fever, although
high spiking fevers are not typical and rather suggest sepsis. Neurolog-
ical symptoms may be present.
The clinicalmanifestation of TA-TMA is extremely variable, but often
the diagnosis ismadepurely based on biochemicalfindings and oliguria,
with patients being asymptomatic or presenting with aspecific
complaints like malaise or headache [14]. Possible symptoms and
biochemical findings are summarized in Table 2. Patients with TA-
TMA are almost always receiving a CNI-based immunosuppressive
regimen. ADAMTS13 levels are not diagnostic, as will be discussed
later.
The differential diagnosis is extensive, as shown in Table 3. Especial-
ly, although beyond the scope of this article, TA-TMA after kidney trans-
plantation is difficult to differentiate from acute rejection or recurrence
of aHUS. Renal biopsy is warranted if the platelet count allows so. In
other SOT recipients, it is recommended to measure at least the pro-
thrombin time, activated partial thromboplastin time and fibrinogen
levels, which ought to be normal. Cytomegalovirus (CMV) serology
must be obtained, since CMV can cause a TMA-like condition character-
ized by thrombocytopenia but without hemolysis. The need for further
diagnostic tests like anti-cardiolipins, lupus anti-coagulants, renal
biopsy, coagulation factors, extended serological testing or others,
is based on clinical judgment. Heparin-induced thrombocytopenia
(HIT) does not cause hemolysis. It must be noted that the presence
of schistocytes is not pathognomonic, as they may also be found inBiochemy
Low hemoglobin and haptoglobin
High reticulocytosis, LDH and indirect bilirubin
Schistocytes
Negative Coombs test
Thrombocytopenia
onfusion
cts
e
▪ High creatinin
opathy after non-renal solid organ transplantation, Blood Rev (2014),
Table 3
Differential diagnosis of thrombocytopenia and microangiopathic hemolytic
anemia.
▪ TMA
▪ Evan's syndrome
▪ Disseminated intravascular coagulation
▪ Preeclampsia, eclampsia
▪ Malignant hypertension
▪ Systemic vasculitis
▪ Anti-phospholipid syndrome
▪ Sepsis
▪ Viral infections (CMV, adenovirus, herpes simplex virus)
▪ Malignancy
▪ Drugs (CNI, ticlopidine, clopidogrel, simvastatin, interferon, quinine)
TMA: thrombotic microangiopathy. CMV: cytomegalovirus. CNI: calcineurin
inhibitor.
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ical conditions [15]. Since they often become detectable only several
days after the onset of TMA, clinicians should not wait for their pres-
ence to make the diagnosis and initiate treatment.
Despite the general definition of TMA, it is of interest that TMA-
lesions in the kidneys have also been found in lung transplant patients
with isolated renal dysfunction [16]. This suggests the need for a low
threshold for renal biopsy in transplant recipients with progressive
renal dysfunction, in whom a change in immunosuppressive regimen
is possible.
2. TA-TMA after different organ transplants
2.1. Methods
PubMed and Google Scholar were searched for combinations of the
following terms: “thrombotic microangiopathy”, “thrombotic thrombo-
cytopenic purpura” or “hemolytic–uremic syndrome”, combined with
“liver transplantation”, “lung transplantation”, “heart transplantation”,
“cardiac transplantation”, “visceral transplantation”, “intestinal
transplantation”, “multivisceral transplantation” or “pancreas trans-
plantation”. For the search of PubMed, MESH-terms were used. The
last search was May 29th, 2014. We withheld every case series and
sufficiently documented case report in English describing patients
with TA-TMA after non-renal SOT. Reports of multi-organ transplan-
tation however were not included, except for intestinal transplant
recipients. Upon finding different reports from the same center and
period in time, we included only the one with the largest number
of patients. No cases of TA-TMA after pancreas transplantation
were found, except for three cases after combined kidney–pancreas
transplantation. These are not discussed. Statistical analysis wasTable 4
Comparison of TA-TMA in different organ transplant recipients.
Liver Lung Visceral
Incidence 4.0% 2.3% ?
Onset⁎ 2 weeks 37 weeks 8 weeks
Survival⁎⁎ 73.6% 71.4% 66.7%
Risk factors⁎⁎⁎ Stop PI b 1 week post
transplantation
HLA-sensitization
ABO-incompatibility
HCV
Splenectomy
Transplantation for FHF
Longer anhepatic phase
History of TMA
Female gender
CNI + mTORi
Concurrent disease
Acute rejection
PI: plasma infusion; HLA: humane leukocyte antigens; HCV: hepatitis C virus; FHF: fulminant h
⁎ Median time of onset after transplantation.
⁎⁎ Three month survival rate.
⁎⁎⁎ Risk factors as identified in the individual transplantations, yet many may be generalized:
phospholipid antibodies.
Please cite this article as: Verbiest A, et al, De novo thrombotic microangi
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data. The incidence rates were calculated based on the number of
cases and total number of patients described in case series. The
median times of onset and survival rates were calculated based on
the times of onset and outcomes reported in both case series and
case reports. Since the only published case series covering TMA
after intestinal transplantation was published by our group, intestinal
transplantation associated TMA is reviewed in more detail, including
one new case report and an overview of the intestinal transplantations
performed at our center. TMA after kidney and hematopoietic stem cell
transplantation will be mentioned briefly. Results are summarized in
Table 4.
2.2. Results
2.2.1. Liver transplantation
Four case series and 18 case reports were found, including a total of
69 adult liver transplant recipients. Two case series and 1 case report
including a total of 5 pediatric patients were found as well [12,17–42].
TMA occurred at a median interval of 2 weeks post-transplantation
(range 0–448). This unusually early onset might be explained by
an imbalance of the vWF/ADAMTS13 ratio the first weeks post-
transplantation, as will be discussed in the section “Pathogenesis of
TMA after solid organ transplantation”. Two authors have described an
elevated ratio of vWF/ADAMTS13 as a potential diagnostic tool [32,
43]. However, this ratio changes depending on the interval after trans-
plantation and presence of other factors like splenectomy, and their
real significance and reference values still need to be determined in
prospective studies [43–46].
The incidence was 4.0% (range 0–7.6%) in adults and 2.4% (range 0–
3.9%) in children. These numbers however are of doubtful value since
hemolysis and thrombocytopenia due to other causes are frequent
after liver transplantation and no uniform criteria for the diagnosis of
TA-TMA exist [37]. This may cause overdiagnosis or, maybe even more
likely, underdiagnosis.
There was a 73.6% survival rate after three months in adults and
57.1% in children. Long term survival was worse after an episode of
TMA, with a 5 year survival rate of 47.7% after TMA versus 87.3% in con-
trols in one series [12]. One case series found a strong correlation
between change of immunosuppression (conversion of CNI) and surviv-
al, whereas PEX was not effective [18]. In another series however, there
was no difference between change of immunosuppression (conversion
or elimination of CNI) and PEX [12].
Risk factors for the development of TMAwithheld after multivariate
analysis were cessation of plasma infusion less than a week after trans-
plantation (OR 2.6, 95% CI 1.1–6.6) and preexisting HLA-sensitization
(OR 16.1, 95% CI 1.7–133). The following risk factors were clinicallyHeart Kidney HSCT
‘Rare’ 0.8–14.0% 8.2%
2 years b3 months 7 weeks
40.0% 80% graft recovery 25–39%
CMV, parvovirus 19
Deceased donor
Anti-phospholipid
antibodies
Female gender
Older age
Unrelated or HLA-mismatched donor
GVHD
Systemic infection
Advanced or refractory disease for which the
transplant was done
epatic failure; GVHD: graft versus host disease.
female gender, concurrent disease, combination of a CNI + mTORi, history of TMA, anti-
opathy after non-renal solid organ transplantation, Blood Rev (2014),
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(HCV) infection, longer anhepatic phase and splenectomy. Transplanta-
tion for fulminant hepatic failure and ABO-incompatibility were strong
risk factors, not tested by multivariate analysis. Perioperative infusion
of a protease inhibitor via the portal vein was suggested to prevent
TMA in ABO-mismatched transplants, but not tested in a controlled
trial [13]. Receptor blood group O was a risk factor as well, which
might be explained by the higher risk to receive an ABO-incompatible
graft. ABO-incompatible transplantation has become rare though in
countries where mainly deceased donor grafts are used. There was a
trend towards increased risk for female gender, mean portal vein flow
b60 cm/s, anhepatic phase N180 min and Model for End-stage Liver
Disease score N14. The use of tacrolimus versus cyclosporin A, age,
blood loss, elevated liver enzymes, CMV infection, acute rejection and
small for size syndrome did not increase the risk [12,13,18,23].
Ten out of 18 cases of TMA described in case reports occurred during
a concurrent acute event like infection or acute rejection. We did not
withhold this because of the high prevalence of such events early after
transplantation. Acute rejection was no risk factor in Shindoh's series.
A decrease in ADAMTS13 has been reported to accompany graft dys-
function so the risk may be elevated in the setting of graft dysfunction
[44].
The following risk factors for poor outcome were withheld after
multivariate analysis: longer interval after transplantation, blood urea
nitrogen before start of treatment, HLA-sensitization and younger age
[12,24]. The importance of a longer interval after transplantation may
be explained by a delay in diagnosis, again stressing the need for high
clinical awareness. Elevated liver enzymes, CMV-positivity and acute
rejection had no prognostic value [12,18].
From a pathophysiological point of view, TMA following liver
transplantation is different from other SOTs because the vWF/
ADAMTS13 ratio is disturbed the first weeks post-transplantation and
CNIs are cleared by the liver. This will be discussed in the section
“Pathogenesis of TMA after solid organ transplantation” in more detail.
Because the liver synthesizes ADAMTS13 and clears CNIs, many au-
thors believe TMA to be more prevalent after LDLT where smaller grafts
are used in adult recipients. It was not possible to deduct this from the
published literature, since all series covered LDLT. Yet it must be men-
tioned that in clinical practice living donor grafts generally show supe-
rior function immediately post-operative in comparison to deceased
donor grafts, except in small for size syndrome, but Shindoh did not
withhold small for size syndrome as a significant risk factor for TA-
TMA [12]. Moreover, as discussed below, consumption of ADAMTS13
by vWF rather than decreased synthesis may be the main problem
and deceased donor grafts after cold preservation could yield more
vWF than living donor grafts. Therefore LDLT may as well not be a risk
factor for the development of TMA. On the other hand, as also discussed
in the section “Pathogenesis of TMA after solid organ transplantation”,
endothelial damage is the key event in the development of TMA. This
damage may be caused by ischemia–reperfusion injury, as is the case
after deceased donor transplantation, but perhaps also by higher stress
on the endothelium of a smaller graft, as is the case after LDLT in adults.
It is therefore uncertain whether a living or rather a deceased donor
graft poses the highest risk, but we believe ischemia–reperfusion or
higher stress on the endothelium to be the main contributing factor
rather than decreased synthesis of ADAMTS13.
2.2.2. Lung transplantation
Four case series and 10 case reports were found, including a total of
63 adult lung transplant recipients [14,47–56].
TMA occurred at amedian interval of 37 weeks post-transplantation
(range 0–134). The incidence was 2.3% (range 0.5%–9.7%), with a three
month survival of 71.4%. Female gender (OR 4.09, 95% CI 1.37–12.2) and
a history of TMA (OR 6.72, 95% CI 2.16–20.9) were significant risk
factors. CMV positivity and the use of tacrolimus versus cyclosporin A
did not elevate the risk [14].Please cite this article as: Verbiest A, et al, De novo thrombotic microangi
http://dx.doi.org/10.1016/j.blre.2014.09.001Fifty percent of the cases occurred during concurrent disease, their
survival rate was only 38.9%. In one series, 13 out of 24 cases occurred
during concurrent disease, but 7 out of 9 deaths occurred in patients
with concurrent disease.
The combination of a CNI and a mammalian target of rapamycin in-
hibitor (mTORi) is sometimes used in lung transplantation. Clinicians
must be aware of the highly elevated risk in comparison to treatment
with CNI alone, the incidence appearing to be 6 to 7 times higher [14,
57].
It is hard to explain why TMA generally occurs late after lung trans-
plantation, in contrast to TMA after other transplants. One hypothesis
could be the frequent association with mTORis in the reported cases.
These drugs are not used in the immediate post-transplant period be-
cause of their adverse effect on wound healing. Since the immediate
danger of TMA after transplantation has passed at the time of their asso-
ciation, the onset of TMA might be quite variable. It was not possible to
derive a trend confirmingor denying this hypothesis from thepublished
literature.
In case reports, TMA after lung transplantation has been noted to be
associatedwith the start ofmacrolide antibiotics and is sometimes pres-
ent as diffuse alveolar hemorrhage [49,51].
2.2.3. Cardiac transplantation
Only 5 case reports of TMA after heart transplantation were found
[27,58–60]. Median time of onset was 2 years after transplantation.
Three out of 5 patients died, the other 2 suffered terminal renal failure
and remained hemodialysis dependent. In 3 patients the precipitating
factor seemed an acute disease, in 2 the only identified risk factor was
a change from Sandimmun ® to Neoral ® about six months earlier,
while they had done well for 7 years [60]. Two patients who were
rechallenged with a CNI after resolution of TMA developed recurrent
TMA. No incidence rates were reported. Parissis reported no cases of
TMA occurring after 680 heart and 65 heart-lung transplants, but the
method of retrospective review was not reported [49].
Thus, occurrence of TMA after heart transplantation is extremely
rare, but its onset can be surprisingly late and the prognosis is poor.
2.2.4. Intestinal transplantation
Intestinal transplantation is by now established as a standard proce-
dure in patients with life-threatening complications due to intestinal
failure and total parenteral nutrition, though results remain inferior to
those of other SOTs [61]. Eight cases of TA-TMA after intestinal or
multivisceral transplantation have been published, one yet unpublished
case occurred at our center [62–65]. Detailed data are provided in
Table 5, which shows a rather strong link with acute rejection.
Median time of onset is 8 weeks post-transplantation. Three
month survival is 66.7%, although all patients who had a fatal out-
come succumbed after resolution of TMA. Eight out of 9 patients suf-
fered from concurrent disease: acute rejection in 7 and infection in 1.
All patients were treated with tacrolimus, 4 were treated with
sirolimus and tacrolimus. Levels of immunosuppressive drugs were
high in 7, due to increased dosing for acute rejection.
Seven had renal failure, only one patient presented with neurologi-
cal symptoms. In one patient, TMA-lesions were manifest in the small
intestine.
At our center, 12 visceral or multivisceral transplantations were
performed between 2000 and 2011, including 2 pediatric patients. All
patients were administered an initial immunosuppressive regimen
consisting of corticosteroids, tacrolimus and azathioprin. Four of these
patients developed TMA. This high number may be explained by high
clinical awareness and a predisposing condition in 2 patients, who suf-
fered from preexisting anti-phospholipid syndrome and Churg–Strauss
vasculitis.
Short term survival was only 50%. One other patient lost her graft
and died 5 years post transplantation. Four of the 12 patients
transplanted since 2000 have died, 3 of them had a history of TMA.opathy after non-renal solid organ transplantation, Blood Rev (2014),
Table 5
Cases of TMA after intestinal transplantation.
Age Gender Reason of transplantation Type of transplantation CNI or mTORi Onset
(weeks)
Concurrent disease
H 34 M Crohn, short bowel syndrome Intestinal Tacrolimus 8 Acute rejection
H 6 F Short bowel syndrome Intestinal + liver Tacrolimus 4 Acute rejection
B 32 F Carcinoid tumor Multivisceral Tacrolimus 5 No
P 36 M Desmoid tumor Multivisceral Tacrolimus + sirolimus 8 Acute rejection
P 44 M Crohn, short bowel syndrome Intestinal Tacrolimus + sirolimus 158 Acute rejection
D 43 M Anti-phospholipid syndrome Multivisceral Tacrolimus + sirolimus 13 Infection
D 34 F Churg Strauss vasculitis Intestinal Tacrolimus + sirolimus 8 Acute rejection
D 41 F Bowel ischemia, post thrombosis Intestinal Tacrolimus 24 Acute rejection
New 48 F Bowel ischemia, post torsion Intestinal + renal Tacrolimus 207 Acute rejection
Hemoglobin
(g/dl)
Platelet count
(/μl)
Lactate dehydrogenase (IU/l) Schistocytes Creatinin ↑ ADAMTS13 Neurological signs
H 7.4 36 1920 ++ Yes NR NR
H NR 26 4990 ++ Yes NR NR
B ‘low’ ‘low’ 9105 ++ Yes NR NR
P 5.8 66 1493 ++ Yes NR NR
P 10 78 180 ++ Yes NR NR
D 7.5 89 5277 b30 Yes 60% Yes
D 8.6 37 1420 12–15 No N100% No
D 7.1 23 975 N20 No 40% No
New 8.9 121 832 N15 Yes Not measured No
Plasma level
tacrolimus
Plasma level
sirolimus
Change of immunosuppression Plasma infusion or
exchange
Resolution Complication Outcome
H NR – Conversion CNI ➔ mTORi Yes Yes Hemodialysis Died, suicide
H NR – Dose reduction No Yes No Alive
B 24.9 μg/l – Stop CNI Yes Yes No Alive
P 15–20 μg/l 5–10 μg/l CNI + PSI ➔ conversion CNI ➔ stop both Yes Yes Acute rejection Alive
P 26.1 μg/l 9.3 μg/l CNI + PSI ➔ dose reduction CNI, stop PSI Yes Yes No Alive
D b2 μg/l 16.6 μg/l Stop CNI Yes Yes Acute rejection Died, rejection and
infection
D 15 μg/l ‘normal’ Stop CNI Yes Yes Graft loss Alive
D 27 μg/l – No change (acute rejection) No Yes No Died, infection
New 10 μg/l – No change (mild form, acute rejection) Yes Yes No Alive
References: H: Humar; B: Banerjee; P: Paramesh; D: Dierickx.
M: male; F: female; NR: not reported.
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ADAMTS13 activity was measured in 3 patients and was normal in
all.
2.2.5. Kidney transplantation
Diagnosis of TA-TMA after kidney transplantation is difficult since it
canmimic acute vascular rejection, recurrence of aHUS or de novo HUS.
De novo TMA after kidney transplantation occurs in 0.8% according
to the United States Renal Data System, but single center studies report
incidences of 4–14%. Graft recovery rate is 80%. Reported risk factors are
CMV-infection, parvovirus 19 infection, deceased donor kidney trans-
plantation, female gender, anti-phospholipid antibodies in HCV-
positive patients and drugs associated with TMA like valacyclovir and
clopidogrel [2,66]. Clopidogrel however is an independent cause of
TMA, not associated with organ transplantation.
2.2.6. Hematopoietic stem cell transplantation
TMA after HSCT can hardly be compared to TMA after SOT. The
etiology is different, with hematologic malignancy and treatment
with chemo- and radiotherapy being important precipitating factors.
Moreover it concerns a vulnerable population, suffering from severe
immunosuppression and other poor prognostic factors. Two sets of
consensus diagnostic criteria have been published, yet the existence of
TMA as a distinct pathologic entity after HSCT has even been doubted
because of the severe confounding factors in diagnosis [3–5].
The incidence is 8.2% with a median time of onset 44 days after
transplantation. Immediate mortality rate is 61–75%, with an elevated
long term mortality as well. Female gender is often reported as a risk
factor. Other risk factors, although reports are contradictive, are graftPlease cite this article as: Verbiest A, et al, De novo thrombotic microangi
http://dx.doi.org/10.1016/j.blre.2014.09.001versus host disease, advanced or refractory disease for which the trans-
plant is done, systemic infections, unrelated or HLA-mismatched donor
and older age. PEX seems to have no proven therapeutic value albeit
randomized controlled trials (RCTs) are lacking. It is therefore not rec-
ommended as a standard of care, but should not bewithheld in patients
with poor prognostic factors [3,5].3. Pathogenesis of TMA after solid organ transplantation
As mentioned in the Introduction, consensus has grown that endo-
thelial damage is the key event in all forms of TMA, which was sug-
gested as early as 1942 [68]. This concept was clearly demonstrated
by Galbusera, who showed plasma samples of patients with acute TTP
induce cytotoxicity and apoptosis of human endothelial cells from the
microvasculature [8].
Among others, nitric oxide (NO) and vascular endothelial growth
factor (VEGF) are of particular importance in protecting endothelial in-
tegrity. It has been shown that mice deficient of endothelial NO develop
TMA-like lesions when aging. In mice-models of HUS, administration of
NO and VEGF has beneficial effects [69].
In this view Goldberg hypothesized how the underlying health of
the endothelium could predispose patients to develop TMA when
exposed to other precipitating events [69]. Therefore maybe not
only treatment by stopping further endothelial damage during
TMA may be warranted, but preventive measures by promoting en-
dothelial health should be considered as well. Possible drugs
exerting this effect could be ACE-inhibitors, vitamin C, statins, allo-
purinol or NO-producing drugs.opathy after non-renal solid organ transplantation, Blood Rev (2014),
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heterogeneity of clinical presentation and moment of onset, ranging
from days to several years after transplantation, indicates the presence
of several pathological mechanisms. Factors being linked with TA-TMA
are the event of transplantation itself, the use of immunosuppressive
drugs, noxious events like acute rejection or infection and a non-
immune relative deficiency of ADAMTS13.
3.1. Transplantation surgery
It seems logical that transplantation surgery itself causes direct endo-
thelial damage. However, this intuitive suggestion does not explainwhy
TMA occurs only after transplantation and not after other surgery. It
seems that theremust be a specific noxious event. Ischemia–reperfusion
injury is the likely culprit, due to both ischemic and inflammatory
mechanisms.
Apoptotic endothelium has indeed been demonstrated to become
pro-coagulative for non-activated platelets, with not only ischemia but
inflammation as well promoting endothelial apoptosis [70]. The most
direct evidence in TA-TMA comes from studies on liver transplantation:
the vascular endothelium turned out to be the primary target for ische-
mia–reperfusion injury, with massive platelet adhesion to the sinusoi-
dal endothelium and increased production of vWF accompanied by
consumption of ADAMTS13 following reperfusion, especially after cold
preservation [45]. Likewise a case of TMA 6 weeks after renal artery
thrombosis has been reported, also suggesting a possible link with
ischemia–reperfusion [71].
Land showed how reactive oxygen species in the allograft, resulting
from brain death and reperfusion injury, turn it into an inflammatory
organwhich activates the host's immune system, probably contributing
to acute and chronic rejection [72]. Moreover, this mechanism not only
seems to be important in the immediate post-transplant period, but
even for years after [73]. These findings could explain why unmatched
living renal allografts yield better results than matched deceased
donor allografts [74]. TA-TMA in renal transplant patients also appears
to be more frequent after deceased donor allograft transplantation,
with its prognosis being more severe [75]. In light of these findings
one can reason that the inflammatory response triggered by ische-
mia–reperfusion injury contributes not only to graft dysfunction and re-
jection, but to TA-TMA aswell. A link between inflammation and TMA is
indeed plausible, since the inflammatory cytokines interleukin (IL) 8
and tumor necrosis factor alpha (TNA-α) stimulate the release of
ultralarge vWF multimers whereas IL-6 inhibits their cleavage [76]. In
sepsis related thrombocytopenia, severity of inflammation and throm-
bocytopenia are correlated with an imbalance between ADAMTS13
and vWF [44]. So even without severe ADAMTS13 deficiency this
might result in TMA in inflammatory circumstances. The frequent
occurrence of TA-TMA during concurrent acute events like infection or
acute rejection further supports this hypothesis.
3.2. Calcineurin inhibitors
Shortly after the introduction of the CNIs cyclosporin A and tacroli-
mus, a link between their use and the occurrence of TMA was recog-
nized. CNIs, though indispensable in current practice, exert their
possibly deleterious effects on the endothelium through various mech-
anisms, including both direct and indirect endothelial injuries and
platelet aggregation. They cause a decrease in vasodilating agents (NO,
prostacyclin), an increase in vasoconstricting agents (endothelin,
thromboxane A2, activation of the renin–angiotensin system), a de-
crease in the formation of activated protein C and increased production
and release of high molecular weight vWF multimers. Cyclosporin A
also increases plasma levels of plasminogen activator inhibitor and pos-
sibly disturbs the function of complement regulatory proteins [2,66,69].
Since tacrolimus and cyclosporin A are metabolized in the liver,
there is an elevated risk of toxic levels in the case of graft dysfunctionPlease cite this article as: Verbiest A, et al, De novo thrombotic microangi
http://dx.doi.org/10.1016/j.blre.2014.09.001or inadequate dosing when a small graft is used. The clearance of tacro-
limus depends on the graft size, its levels being higher for the samedose
after LDLT. The optimal dose of tacrolimus can be calculated based on
the graft volume versus standard liver volume ratio [28].
Some have reported the risk of TA-TMA in renal transplants to be
higher for cyclosporin A compared to tacrolimus, but this has not been
observed by others [77,78]. In liver and lung transplantation, there
seems to be no difference [14,24].
Importantly, supratherapeutic levels of CNIs have been reported in
only a minority of the cases we analyzed.
Apart from causing TA-TMA, CNIs also exert a direct nephrotoxic
effect. Ten percent of non-renal SOT patients develop end-stage
renal disease within 10 years after transplantation [79]. Lefaucheur
reported a series of 15 lung transplant patients, 93.3% of whom had
signs of CNI-toxicity on renal biopsy. Moreover, in 46.7% renal biopsy
showed TMA-lesions even though none of the patients developed
hemolysis or thrombocytopenia [16].
3.3. mTOR inhibitors
TA-TMA has been reported in patients receiving mTORis alone as
well as in combination with CNIs. Several studies have shown the risk
of TA-TMA to be remarkably higher when a combination of an mTORi
and a CNI is used, with many reports originating from series of lung
transplant recipients [14,55,79–81].
The most important mechanism probably is mTORi-induced down-
regulation of VEGF, which may directly cause TMA or impair the repair
of endothelial damage caused by CNIs. This is supported by the finding
that administration of bevacizumab, a monoclonal anti-VEGF antibody,
causes severe thrombotic glomerular damage inmice [69]. In humans, 6
cases of bevacizumab associated TMA have been reported [82]. Fur-
thermore, mTORis also cause direct endothelial damage and platelet
aggregation, though not as markedly as cyclosporin A [80,83].
3.4. Interfering disease
In a considerable proportion of patients with TA-TMA, the condition
developed during the course of another stressful event like acute rejec-
tion or infection, or was associated to the administration of certain
medications.
The same mechanism of endothelial damage through inflammatory
conditions, as discussed above, seems to apply, in combination some-
times with a more specific pathological effect. The presence of antibod-
ies and immune complexes for example, as in acute rejection, can
induce endothelial injury and trigger massive sequestration of platelets
and polymorphonuclear leukocytes in the microcirculation [8].
As observed in several case reports, a typical case of TA-TMA is a pa-
tient on an immunosuppressive regimen containing a CNI and perhaps
an mTORi, who experiences an episode of acute rejection or infection
in the first weeks post-transplantation. Thus, in most patients several
risk factors are present at the same time when TA-TMA develops.
3.5. Relative ADAMTS13 deficiency
Primary TTP is caused by autoantibodies against ADAMTS13,
resulting in an increase in ultralarge vWF multimers. PEX removes
these antibodies and substitutes ADAMTS13, thereby increasing surviv-
al from 10% to 80% [6]. For this reason a deficit of ADAMTS13, immune
or non-immune, has been hypothesized to be responsible for TA-TMA
as well. However, no convincing evidence is present and RCTs measur-
ing ADAMTS13 activity or investigating the effect of PEX are warranted.
In our literature search of TMA after non-renal SOT, we found 11
cases in which ADAMTS13 activity was reported. It was normal in 8,
temporarily reduced without correlation to the clinic in 1 and b5%
with the presence of an inhibitor in 2 [14,23,25,51,63]. One of these
two patients was treated with PEX but did not respond and succumbed,opathy after non-renal solid organ transplantation, Blood Rev (2014),
7A. Verbiest et al. / Blood Reviews xxx (2014) xxx–xxxwhereas the other responded to PEX and discontinuation of tacrolimus,
but relapsed when cyclosporin Awas introduced, this timewith normal
activity of ADAMTS13 without inhibitor. Pham described a case of TMA
in a renal transplant patient with undetectable ADAMTS13 levels and
presence of an inhibitor, who responded to PEX and discontinuation of
cyclosporin A [84].
The observation that only a minority of patients presents low
ADAMTS13 activity and an inhibitor when measured, suggests another
pathological mechanism in TA-TMA compared to primary TTP. It is
possible that in the few cases reported, inhibitors had been present
even before transplantation, but increased due to the inflammatory-
enhancing effect of transplantation surgery. Notably all three cases
occurred in the first days after transplantation.
In contrast to an autoimmune mediated absolute deficit of
ADAMTS13, a relative deficit has also been suggested to contribute to
the pathogenesis of TA-TMA. Several arguments support this hypothe-
sis. It is well known that endothelial injury may result in a widespread
release of unusually large vWF multimers, thus causing a relative defi-
ciency of ADAMTS13 [11]. We already mentioned how inflammatory
cytokines contribute to the formation of ultralarge vWF multimers as
well. Moreover, 10% of TMAs in general occur during pregnancy or in
the postpartum period, when an increase in vWF and a decrease in
ADAMTS13 are noted [69].
This relative ADAMTS13 deficiency seems to be of special impor-
tance in TMA after liver transplantation. Patients with liver dysfunction
suffer from dysregulation of the hemostatic system, with among others
a decrease in ADAMTS13 and increase of vWF [46]. Low levels of
ADAMTS13, which is synthesized in the stellate cells of the liver, are
known to be a marker of liver disease [85]. Moreover, a decreased
ADAMTS13 level after liver transplantation has been shown to be a
marker of graft dysfunction and correlated with prolonged thrombocy-
topenia [44].
Several authors have reported a decrease of ADAMTS13 and, to a
lesser extent, an increase in vWF after liver transplantation, thus leading
to an imbalance in the vWF/ADAMTS13 ratio and possibly a hypercoag-
ulable state. The responsible mechanism seems to be the massive re-
lease of hyperactive vWF by the injured sinusoidal endothelium after
reperfusion and parallel consumption of ADAMTS13. This may lead to
a “local TMA”, with thrombocytopenia but without systemic hemolysis
or renal failure [43–46].
It is plausible that patients with such a pronounced “local TMA” are
at risk for developing a full blown systemic TA-TMA,whereas it could be
a self-limiting phenomenon in others. In one small series and one pro-
spective study, patients experiencing TMA after liver transplantation
had a markedly more elevated vWF/ADAMTS13 ratio compared to
others and the authors postulated this ratio to be of diagnostic value
[32,43]. Moreover, the median time of occurrence of TMA after liver
transplantation, as we found in the literature, is at two weeks post-
transplantation, themomentwhen the vWF/ADAMTS13 ratio is highest
[43].
Is this mechanism really much more important in liver transplant
patients than in others? It must be noted that the vWF/ADAMTS13
ratio has, to our knowledge, not yet been investigated in other trans-
plants. This is a research topic that certainly deserves attention in the
future. Yet, the fact that TMA tends to occur early after liver trans-
plantation, which is only the case in a minority of patients after
other SOTs, supports the idea that this imbalance is more important
in liver transplant recipients. Why would this be? After all, one
would expect that vWF release by ischemic endothelium, with con-
sumption of ADAMTS13, could occur after any SOT — perhaps even
more so after lung transplantation where deceased donor grafts are
used, whereas the reports in liver transplantation are mainly from
LDLT series. There are several possible reasons. Firstly, an imbalance
between vWF and ADAMTS13 is present in patients with liver dys-
function even before transplantation, which could augment the
effect post-transplantation. Secondly, ADAMTS13 is synthesized inPlease cite this article as: Verbiest A, et al, De novo thrombotic microangi
http://dx.doi.org/10.1016/j.blre.2014.09.001the liver, so graft dysfunction could lead to decreased levels (there
are several strong arguments, beyond the scope of this review, that
stress extensive consumption as the main contributing factor, but
this is especially the case immediately post-operative) [45]. A third
possibility could be that the endothelium of the liver is more prone
to ischemia–reperfusion injury than that of other organs, thus
releasing more vWF. The finding of massive platelet aggregation in
the microcirculation shown after liver transplantation strongly sup-
ports this hypothesis [45]. Moreover smaller grafts are used in adults
receiving living donor grafts, thus causing higher stress on the endo-
thelium. Finally, since hemolysis and thrombocytopenia are fre-
quently seen shortly after liver transplantation for various reasons,
TA-TMA may be overdiagnosed. This last possibility is far from
certain however, it could just as well be a reason for underdiagnosis.
4. Prevention and therapy
4.1. Prevention
In general, the use of statins, ACE-inhibitors, vitamin C or othermed-
icationswith stabilizing effects on the endotheliummight reduce the in-
cidence of TMA, but no studies addressing this question are available. In
light of the findings discussed above, prevention by careful surgery and
anesthesia, tight control of CNI levels, prevention of acute rejection and
infection, especially HCV in liver transplants, are important.
As for liver transplantation, we hypothesized above how a decrease
in ADAMTS13 probably plays a major role in the development of TA-
TMA early after liver transplantation. The level of ADAMTS13was corre-
latedwith the risk of TA-TMA [43]. Substituting ADAMTS13 can be done
by administering plasma derivates. Indeed, the cessation of fresh frozen
plasma (FFP) therapy within one week post-transplantation was a risk
factor for TA-TMA after multivariate analysis in one series [12]. In one
series of 20 liver transplant patients, the 3 with low ADAMTS13 had
been transfused with packed red cells instead of FFP. Interestingly, the
one with lowest ADAMTS13 on day 1 post-operatively, developed
hepatic artery thrombosis on day 2 [46].
Although plasma derivates are rarely used after surgery the first
week, TA-TMA may be prevented by continuing plasma infusion for at
least a week after transplantation. Perioperative infusion of a protease
inhibitor via the portal vein might be useful in ABO-incompatible trans-
plants, but this has not been validated in clinical practice.
4.2. Change of immunosuppression
Since CNIs and less frequently mTORis constitute the most impor-
tant risk factor for TA-TMA, change of immunosuppressive regimen is
pivotal in its treatment. This change may be discontinuation of CNIs,
dose reduction or conversion.
If possible, the CNI should be substituted by an immunosuppressive
agent not linked with TMA, like mycophenolate mofetil (MMF),
azathioprin or cyclophosphamide. MMF and azathioprin have the im-
portant advantage of being not nephrotoxic.
Ifmaintenance of strong immunosuppression is needed, for example
in the case of acute rejection, temporary administration of high doses of
corticosteroids is often successful. In mild forms of TA-TMA where
discontinuation of the CNI is not feasible, dose reduction may suffice
in selected patients [64,65].
An alternative approach when continuation of a CNI is needed is
conversion from tacrolimus to cyclosporin A or vice versa. In 63 of the
cases after non-renal SOT we analyzed, patients were converted to the
other CNI. Sixty of them had good outcomes, which is even higher
than average, possibly because mainly patients with a mild form of
TMA were converted.
After resolution of TMA, the causative CNI may be reintroduced
safely if needed. In a series of kidney transplant patients, 19 out of
20 rechallenges proved successful [86]. There still remains a riskopathy after non-renal solid organ transplantation, Blood Rev (2014),
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out of 5 heart transplant patients we analyzed, developed recurrent
TMA at rechallenge [27,58–60].
In cases where the immunosuppressive regimen is not altered, due
to late recognition or unfavorable circumstances, prognosis is poor.
Twelve patients of the cases we analyzed were treated with PEX alone,
but only 6 survived. Notably only 3 out of 12 experienced concomitant
acute rejection impeding stop of CNI, but 2 out of 3 survived. Thus, the
presence of acute rejection does not seem to be the major cause of
poor outcome in patients without adaptation of immunosuppression.
In patients treated with the combination of a CNI and an mTORi it
seems safe to discontinue only the mTORi when TMA develops shortly
after its introduction [14,79].
4.3. Therapeutic plasma exchange
Historically, PEX has grown to be a standard of care in TMA, because
of its superiority in the treatment of primary TTP. By now however, the
lack of its effect in HUS has long been shown and it has become clear
that the etiology of TA-TMA as well is very different from that of TTP
[7]. Since autoantibodies against ADAMTS13 are not present in TA-
TMA, there seems to be no rationale for the systematic use of PEX.
Unfortunately, RCTs in this rare condition are lacking and clinicians
are reluctant not to administer a possibly useful therapy in such a seri-
ous condition. Yet one must keep in mind the potential adverse effects
of PEX in these already seriously ill patients: thrombosis, bleeding,
infection, anaphylaxis, pneumothorax or hypotension [87]. George
reported that 24% of patients treatedwith PEX suffered amajor compli-
cation. Although this number tended to decrease over the years, this
was only the case for patients with primary TTP. In those with a normal
ADAMTS13 level, the complication rate remained unchanged. He attrib-
uted this to the fact that patients with normal ADAMTS13 do not clearly
respond to PEX and thus receive more sessions [88].
According to the American Society for Apheresis guidelines, the role
of apheresis for CNI-associated TMA is not established and its initiation
should be based on individualized decision making. Moreover, the evi-
dence to support this guideline is weak [89].
In HSCT, although RCTs are lacking, large series have not shown a
beneficial effect of PEX and it is not considered standard therapy [4].
In renal transplantation, an advantage of PEX has been reported sporad-
ically in small series [86]. In our analysis of non-renal SOT, data are too
heterogeneous to draw firm conclusions. Some observed that conver-
sion of CNI is the key to resolution, whereas others found no difference
between PEX or CNI conversion [12,18,32]. In 12 case reports of patients
treated only with PEX, outcome was worse. Of 2 patients with low
ADAMTS13 level and an anti-ADAMTS13 inhibitor at presentation, one
was treatedwith PEX and conversion and survived; the otherwas treat-
ed only with PEX but died [51]. Lovric treated every patient with a
sudden decrease in renal function or TMA-lesions on renal biopsy
with PEX and all patients experienced at least a temporary improve-
ment of renal function [79].
Theoretically, PEX could have beneficial effects through the substitu-
tion of ADAMTS13 or a yet unknown plasma factor, or by removing a
noxious factor like angiopoietin-2 [57].
Early after liver transplantation, when ADAMTS13 deficiency ap-
pears to play a major role, administration of FFP should be an integral
part of the therapeutic approach in our opinion, though this has not
yet been tested in RCTs. PEX is known to improve prognosis of post-
operative liver failure and may prove advantageous to prevent volume
overload or renal failure by removing bilirubin when this is severely el-
evated. One should be cautious though since severe hepatic sinusoidal
damage could facilitate PEX-mediated induction of hypercoagulopathy
in a setting where coagulation is already disturbed. Two case reports
have been published describing patients without TMA who suffered le-
thal hepatic artery thrombosis after initiation of PEX for post-operative
hepatic failure [90].Please cite this article as: Verbiest A, et al, De novo thrombotic microangi
http://dx.doi.org/10.1016/j.blre.2014.09.0014.4. Supportive care
Apart from treating precipitating factors like infection, TA-TMAmay
be managed by transfusion of packed red cells, folic acid supplementa-
tion during hemolysis and lowmolecular weight heparin when platelet
count exceeds 50000/μl.
Platelet transfusion is generally not recommended in the absence of
active bleeding or a planned invasive procedure, as this might increase
the risk of thrombosis. However a recent review of platelet transfusion
in TTP did not show an adverse effect [91]. Splenectomy is not useful
and has even been reported to increase the risk of TA-TMA [12].
4.5. Experimental therapies
Alternative drugs when substituting CNIs could be monoclonal anti-
bodies like the anti-CD25 antibodies dacliximab or basiliximab or the
anti-CD52 antibody alemtuzumab. These antibodies are not directly
cytotoxic to the endothelium, so theymay be anoptionwhen classic im-
munosuppressive therapy is not possible.Wolff treated 13 patientswho
developed TMA after HSCT with daclizumab and discontinuation of
CNIs. Nine of these patients obtained complete remission and 2 partial
response [92]. Togashi reported 3 patients with TMA after LDLT who
responded well to substitution of CNIs with basiliximab [93].
Eculizumab, an anti-C5 antibody, is useful in aHUS associated with
mutations in complement regulating genes and its recurrence after
transplantation. There is no rationale for using it in TA-TMA, although
one case has been reported with resolution of kidney transplantation
associated TMA after eculizumab therapy [94]. This patient did not
have any mutations associated with aHUS and had not responded to
PEX or conversion of CNI.
Rituximab, an anti-CD20 antibody, is often used in primary TTP to
halt production of anti-ADAMTS13 antibodies, but has no theoretical
advantage in TA-TMA [95]. One case report has suggested the possibility
of belatacept, a selective T-cell activation blocker, as an alternative im-
munosuppressive drug [96]. Furthermore defibrotide, which possesses
profibrinolytic, anti-thrombotic, anti-inflammatory and anti-ischemic
properties, is used in sinusoidal obstructive syndrome. In one series,
12 patients suffering from TA-TMA after HSCT were treated with
defibrotide. Nine of them responded. Some other small series in HSCT
have reported positive results [87]. Theoretically, an advantage of
VEGF, TNF-α blockers or NO-donors could be expected.
5. Discussion
TMA is a histopathological term referring to a whole spectrum of
diseases with endothelial damage as the common etiological factor.
This results in typical endothelial lesions and formation of platelet
rich thrombi in the microvasculature, especially in the glomeruli.
The specific etiology of TA-TMA remains unresolved but is associated
with endothelial damage and inflammation due to ischemia–reperfusion,
immunosuppressive drugs and certain other precipitating events like in-
fection or acute rejection. A relative deficit of ADAMTS13 for various rea-
sons, especially early after liver transplantation, may as well play a
causative role but needs further investigation by studies measuring the
vWF/ADAMTS13 ratio in transplant patients with and without TA-TMA.
TA-TMA seems to occur in about 2–4% of solid organ recipients and 8%
of HSCT. Survival is about 70% for liver, lung and intestinal transplant
recipients,N80% after kidney transplantation but only 25–39% after
HSCT. Patients often do not die directly fromTMA, but fromother compli-
cations. In pediatric liver transplantation, the incidence seems to be lower
but the prognosis is worse. The most important complications in survi-
vors are graft loss and terminal renal failure.Moreover long term survival
is significantly worse in patients with a history of TMA.
TA-TMA generally occurs within the first 3 months after transplan-
tation but the risk remains present for years afterwards. It occurs partic-
ularly early after liver transplantation, with amedian time of onset afteropathy after non-renal solid organ transplantation, Blood Rev (2014),
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occurs rather late after lung and heart transplantations, maybe because
of the immunosuppressive regimen used in lung transplantation and its
very rare occurrence after heart transplantation.
Uniform diagnostic criteria are lacking, yet early diagnosis and treat-
ment determine prognosis. In general, the presence of thrombocytope-
nia and Coombs negative hemolytic anemia without other explanation
in a SOT recipient, is considered to be TA-TMA. Most patients suffer
from renal insufficiency as well. Clinical symptoms like fever, neurolog-
ical signs, visual disturbances or abdominal pain may be variably mani-
fest but often are not present at all. Only a minority of patients presents
with supratherapeutic levels of immunosuppressive drugs. Differential
diagnosis is extensive, especially acute vascular rejection or HUS after
kidney transplantation or DIC and CMV-infection after any transplanta-
tion should be excluded. Further diagnostic testingdepends on the clini-
cians' best judgment. A sharp drop in platelet count is rather suggestive
of TMA. An elevated vWF/ADAMTS13 ratio shows diagnostic value early
after liver transplantation, but still needs validation and reference
values have not yet been determined.
Acute disease like infection or acute rejection increases the risk of
TA-TMA and worsens its prognosis. Therefore clinicians should be
extra alert for signs of TMA in this setting. The only exception seems
liver transplantation, where the occurrence of TMA and its prognosis
were not associated with acute rejection [12]. This might be explained
by the early onset after liver transplantation, when such acute events
are common in control patients as well.
Important other risk factors for TA-TMA are the combination of CNIs
with an mTORi and predetermining conditions like a history of TMA or
anti-phospholipid antibodies. Female gender slightly increases the risk.
Importantly, CMV-positivity was never withheld as a risk factor after
non-renal SOT, although it has been reported to increase the risk after
kidney transplantation. In liver transplantation, specific risk factors are
cessation of plasma infusion within one week after transplantation,
HLA-sensitization, ABO-incompatibility, HCV-infection, transplantation
for fulminant hepatic failure and splenectomy. LDLT has been hy-
pothesized to be a risk factor because of a smaller size of the graft,
but no comparison with deceased donor liver transplantation could
be made and there are several arguments against this idea as well.
Theoretically, graft dysfunction could be a risk factor but this has
not yet been assessed.
Early recognition and treatment are of vital importance for survival,
with the most important factor in treatment being change of immuno-
suppression. This includes cessation of CNIswhen possible. A valid alter-
native is conversion to another CNI when cessation is impossible, in the
cases we analyzed 60 out of 63 patients treated with conversion had
good outcomes. For mild forms dose reduction may suffice in selected
patients.When onset is clearly associated with start of anmTORi, cessa-
tion of the mTORi may be sufficient as well. After the resolution of TA-
TMA, rechallenge with a CNI is generally safe, except maybe in heart
transplant recipients.
PEX is the standard of care in acquired TTP, but has no proven value
in TA-TMA. RCTs are lacking and sporadic case reports and small series
often report contradictive results. In the cases we analyzed, patients
treatedwith PEX alonehad poorer outcomes except in one series.More-
over thepotential adverse effects of PEX should be kept inmind. InHSCT
it is no longer recommended as a standard of care. We would therefore
recommend starting PEX only in those SOT recipients with poor
prognostic factors. The presence of an ADAMTS13 inhibitor should be
ruled out though, since it is present in some patients with seemingly
transplant associated TMA. Early after liver transplantation, where
TMA is associated with early stop of plasma infusion after transplanta-
tion and a decrease of ADAMTS13, we would recommend FFP-infusion
and PEX if needed as a standard of care in the absence of further studies.
Prevention of TMA by careful surgery and anesthesia, tight control of
CNI levels, prevention of acute rejection and infection, especially HCV in
liver transplants, and administration of FFP after liver transplantationPlease cite this article as: Verbiest A, et al, De novo thrombotic microangi
http://dx.doi.org/10.1016/j.blre.2014.09.001are important. Further study is needed for optimization of underlying
endothelial health by drugs like statins, NO-donors, ACE-inhibitors or
vitamin C and for prevention of oxide free radicals mediated damage
by perioperative treatment with a superoxide scavenger.
6. Conclusion
TA-TMA is a rare but serious complication of organ transplantation
and its early recognition and treatment are of vital importance. Diagno-
sis is made based upon the presence of thrombocytopenia and Coombs
negative hemolytic anemia without a more likely explanation in a SOT
recipient. The most important therapeutic intervention is a rapid
change of immunosuppressive therapy. RCTs are needed to evaluate
the value of PEX, but currently we would only recommend it as a stan-
dard of care early after liver transplantation and in patients with poor
prognostic factors. Further studies for interventions that could reduce
the risk of TA-TMA and for investigation of the diagnostic value of the
vWF/ADAMTS13 ratio in different transplants and at different intervals
after transplantation are needed.
Practice points
• Thrombocytopenia and Coombs-negative hemolytic anemia in a SOT
recipient without a more likely explanation is considered to be TA-
TMA. Apparition of schistocytes may be delayed. Renal dysfunction
is present in most patients, clinical symptoms are not.
• TA-TMA mostly occurs in the first 3 months post-transplantation,
after liver transplantation even during the first weeks, but the risk
remains present for several years.
• Acute events like infection or acute rejection elevate the risk of TA-
TMA and may mask its diagnosis.
• CNIs are the most important risk factor, association of an mTORi
elevates the risk.
• Early treatment is important.
• Change of CNI (discontinuation, dose reduction, conversion) and
mTORi treatment is the most important therapeutic factor.
• We recommend the infusion of FFP or PEX as a standard of care in
TMA early after liver transplantation, in other settings the value of
PEX is controversial.
Research agenda
• Determination of the therapeutic value of PEX.
• Determination of the prophylactic and therapeutic value of FFP in TA-
TMA early after liver transplantation.
• Search for CNI-saving immunosuppressive protocols, for example
using monoclonal antibodies.
• Determination of the diagnostic value of the vWF/ADAMTS13 ratio for
TA-TMA after liver transplantation and determination of reference
levels at different intervals post-transplantation.
• Investigating the vWF/ADAMTS13 ratio in TA-TMA after non-liver
SOT.
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